Spotlight Series on Hepatitis C

Medical News

Wisconsin: Treatment of Hepatitis C Can Be Successful in a Prison Population

October 10, 2012

Study results are currently showing that incarcerated individuals with chronic hepatitis C virus (HCV) infection can be successfully treated with pegylated interferon and ribavirin, and have achieved comparable rates of treatment completion and sustained viral response to those outside the correctional setting. HCV infection within incarcerated populations has reached as high as 31 percent, compared with 1.6 percent of the general population, leading researchers to suggest that anti-viral treatment while incarcerated is optimal.

No study had compared treatment with pegylated interferon and ribavirin between contemporaneous incarcerated and community patients treated at the same clinic until Michael Lucey (University of Wisconsin, Madison, USA) and colleagues evaluated 388 incarcerated and 521 nonincarcerated HCV-infected patients for treatment at the University of Wisconsin clinics between January of 2002 and December of 2007. Overall, 386 (69.8 percent) patients completed a full treatment course, and a similar proportion of incarcerated and nonincarcerated completed a full treatment course (75 percent and 68.6 percent, respectively). Additionally, a sustained viral response (SVR) was achieved in a similar number of both incarcerated (42.9 percent) and nonincarcerated (38 percent) patients.

The study shows that prison offers potential access to appropriate HCV care for a population with numerous socioeconomic, psychiatric, and substance abuse factors.

Back to other news for October 2012

Adapted from:
10.08.2012; Andrew Czyzewski

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.